DiscoverIPO

Latigo Biotherapeutics, Inc.

expected
Aug 6, 2026
status
Expected
proposed ticker
LTGO
Industry
Pharmaceutical Preparations
Headquarters
United States
Incorporated in
DE
Exchange
NASDAQ
Price range
$16.00 – $18.00
Shares offered
16.0M shares
Offer size
$313M
Underwriters
GS, JEFFER, LEER, GUGGEN

Overview

Business overview

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medications that aim to effectively inhibit pain transmission without the risk of addiction. The company's lead product candidates, LTG-001 and LTG-321, are Na v 1.8 inhibitors targeting musculoskeletal pain and chronic pain, respectively, with a particular focus on areas of significant unmet need.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

  • Innovative non-opioid pain medicines
  • Advanced clinical-stage candidates for pain management
  • Positive clinical trial results demonstrating efficacy and safety
  • Focus on unmet needs in both acute and chronic pain sectors
  • Experienced management team in pain biology and clinical translation

Risk factors

  • Dependence on regulatory approval for product candidates
  • Clinical trial outcomes may not meet expectations
  • Competition from existing pain management solutions
  • Potential for high research and development costs.
  • Market acceptance of non-opioid alternatives is uncertain.

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

Latigo Biotherapeutics, Inc.'s offering is currently expected on NASDAQ. The expected date is Aug 6, 2026. Shares are expected to be offered at $16.00 – $18.00, with 16.0M shares on offer, for a total offer size of $313M. The proposed ticker is LTGO. Underwriters on the deal include GS, JEFFER, LEER, GUGGEN. Latigo Biotherapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Latigo Biotherapeutics, Inc. has filed 4 times, starting with a S1/A on Aug 3, 2026.

Frequently asked questions

When is Latigo Biotherapeutics, Inc. expected to go public?

Latigo Biotherapeutics, Inc. is expected to list on Aug 6, 2026.

What exchange will Latigo Biotherapeutics, Inc. list on?

Latigo Biotherapeutics, Inc. is listing on NASDAQ.

How much is Latigo Biotherapeutics, Inc. raising in its IPO?

Latigo Biotherapeutics, Inc.'s offering is expected to raise $313M.

What is Latigo Biotherapeutics, Inc.'s ticker symbol?

Latigo Biotherapeutics, Inc.'s proposed ticker is LTGO.

Where this data comes from

New York Stock Exchange listings data. Retrieved Aug 3, 2026.

View the original filing on NYSE →

All filings for this company

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.

We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy